Testing a new medication to reduce flare-ups in lung disease patients

Plain-English translation of NCT07349524 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called RSS0343 to see if it can help people with COPD — a serious lung disease that makes breathing difficult — by reducing the number of severe flare-ups they experience. The study will compare the medication to a placebo (a dummy pill with no active ingredient) over 48 weeks to measure how well this treatment works and whether it is safe.

Many people with COPD experience frequent, serious flare-ups that get worse over time and require emergency care. This study exists to see whether this medication could help prevent those flare-ups and improve quality of life for people living with this condition.

Do you qualify?

You likely qualify if…

you are between 40 and 80 years old
you have been diagnosed with COPD for at least 12 months
you have had at least one serious flare-up of your lung disease in the past year
you are currently taking standard COPD medications (either two or three medicines together) and have been stable on them for at least 3 months
you have a current or former smoking history of at least 10 pack-years

You likely don't qualify if…

you are currently taking certain immune-suppressing medications or biologic therapies
you have had lung surgery or procedures for chronic bronchitis within the past year
you require supplemental oxygen for more than 15 hours per day or use a breathing machine
you have participated in another drug trial within the past 3 months
you are pregnant, nursing, or unwilling to use effective birth control during the study

What participation looks like

You will have a 4-week screening period where doctors will confirm you qualify, then 48 weeks of treatment where you will take either the new medication or a placebo by mouth and visit the clinic for check-ups and breathing tests. After treatment ends, you will have a 4-week follow-up period to make sure everything is okay. Throughout the study, you will be monitored to see how many flare-ups you have and whether the medication is safe.

AI-generated summary from trial data · Jun 20, 2026 · Not medical advice

Trial locations(1 site)

China

First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong